BIOTECH (1) – BIO TALK
BIOTECH (2) – Moderna
BIOTECH (3) – Ionis Pharmaceuticals
BIOTECH (4) – Alnylam
BIOTECH (5) – Alzheimer 치료제
BIOTECH (6) – Mirati Therapeutics
BIOTECH (7) – Moderna INT (Individualized Neoantigen Therapy) 임상2b상 결과
BIOTECH (8) – Wave Life Sciences의 RNA Editing 신약 가능성에 GSK가 투자하다.
BIOTECH (9) – Precision Biosciences의 Allogeneic CAR-T 치료제
BIOTECH (10) – Madrigal Pharmaceuticals의 NASH 치료제 MGL-3196 (Resmetirom) 임상 3상 결과
BIOTECH (11) – Eisai/Biogen Lecanemab (BAN2401) Alzheimer 치료제
BIOTECH (12) – Intellia Therapeutics In Vivo Gene Editing
BIOTECH (13) – 생명과학 발전 국가별 기여도 Nature Index-Life Science
BIOTECH (14) – SK그룹의 BIO 전략 – SK Bioscience & SK Pharmteco
BIOTECH (15) – ProQR의 RNA Editing 기술에 Eli Lilly가 $75M 투자하다.
BIOTECH (16) – LegoChem Amgen과 ADC항암제 $1.2B 계약
BIOTECH (17) – Daiichi Sankyo의 mRNA COVID-19 Vaccine DS-5670 임상3상 성공, 2023년 1월 신약승인신청
BIOTECH (18) – Oric Pharmaceuticals의 CD73 저해제 ORIC-533에 Pfizer가 $25M 지분 투자
BIOTECH (19) – 생명과학 투자하기
BIOTECH (20) – Atara Biotherapeutics의 Off-the-shelf CAR-T Ebvallo EU 승인
BIOTECH (21) – 2022년도 Top5 주가상승률을 보인 Biotechs
BIOTECH (22) – Top 10 Biotech with Hedge Funds
BIOTECH (23) – FDA 신약 승인 2015-2022
BIOTECH (24) – Vir Biotechnology
BIOTECH (25) – Moderna가 OriCiro Genomics를 인수
BIOTECH (26) – Geron의 Telomerase inhibitor, Imetelstat 임상3상 결과
BIOTECH (27) – Allogene Therapeutics의 Allogenic CAR-T 치료제 개발
BIOTECH (28) – 유전자치료제 회사 Bluebird Bio
BIOTECH (29) – Intercept의 NASH 신약 Ocaliva (Obeticholic Acid) NDA 신약승인심사일 6/22/2023
BIOTECH (30) – Daiichi Sankyo mRNA Vaccine 2천만회 분 공장 설립 – 2024년 완공 예정
BIOTECH (31) – Aligos Therapeutics Restructuring from HBV to NASH & COVID
BIOTECH (32) – Aera Therapeutics
BIOTECH (33) – Verve Therapeutics
BIOTECH (34) – 2040 Future of Biotechnology
BIOTECH (35) – The Entrepreneur’s Guide to a Biotech Startup
BIOTECH (36) – How to Start and Grow a Life Sciences Company
BIOTECH (37) – Seres Therapeutics
BIOTECH (38) – LYTAC Platform Startups: Lycia vs Avilar
BIOTECH (39) – 한미약품/Spectrum의 Poziotinib의 FDA 불승인 원인에 대한 생각
BIOTECH (40) – Circular RNA Platform – Orbital vs Laronde vs Orna Therapeutics
BIOTECH (41) – Arrowhead Pharmaceutical’s Pulmonary siRNA Platform
BIOTECH (42) – CRISPR 2.0 Platform
BIOTECH (43) – 일본 제약 BIO에서 배우기
BIOTECH (44) – Moderna의 창업 Story
BIOTECH (45) – 일본 제약BIO 배우기 – SNBL의 Wave Life Sciences Incubating Case Study.
BIOTECH (46) – Tessera Therapeutics 창업 Story
BIOTECH (47) – Moderna Story from Media
BIOTECH (48) – Sana Biotechnology Story
BIOTECH (49) – Laronde Story
BIOTECH (50) – Alltrna Story
BIOTECH (51) – Mammoth Biosciences Story
BIOTECH (52) – Palleon Pharmaceuticals: : Sialoglycan degradation platform
BIOTECH (53) – CRISPR-Cas 좋은 Review
BIOTECH (54) – ReNAgade Therapeutics – Moderna ReUnion
BIOTECH (55) – CRO-Venture Capital Model
BIOTECH (56) – Nkarta Therapeutics: CAR-NK의 미래 (1부)
BIOTECH (57) – LG화학의 Aveo Oncology 인수에 대한 생각
BIOTECH (58) – 삼성과 Flagship Pioneering의 전략적 제휴
BIOTECH (59) – Sail Biomedicine by merger of Laronde and Senda Biosciences
BIOTECH (60) – Umoja Biopharma’s in vivo CAR-T Platform
BIOTECH (61) – 레고켐바이오사이언스 김용주대표의 큰 그림
BIOTECH (62) – Unnatural Products Inc의 Macrocyclic Peptides
BIOTECH (63) – Ascidian Therapeutics의 RNA Exon Editing or Splicing Editing
BIOTECH (64) – Amber Bio의 Splicing Editing
BIOTECH (65) – Intellia Therapeutics 3-year strategic priorities
BIOTECH (66) – ChulaCOV19 태국 최초 개발 mRNA COVID-19 Vaccine
BIOTECH (67) – Dr. Shakked Halperin – Tiniest Platform Biotech
BIOTECH (68) – Autolus Therapeutics Obe-cel as fast-off CD19 CAR-T therapy
BIOTECH (69) – Abclon AT101 – h1218 CAR-T19 Phase 1 Data
BIOTECH (70) – GSK의 Bepirovirsen/JNJ-3989 Combo Strategy for HBV functional cure
BIOTECH (71) – Expansion Therapeutics – RIBOTAC Degrader by RNA-Small Molecule Binding
BIOTECH (72) – Epic Bio: Epigenetic Editing
BIOTECH (73) – 2Seventy Bio의 Programmable CAR-T Clinical Hold
BIOTECH (74) – Obsidian Therapeutics OBX-115 (on-switch cytoTIL15 Therapy)
BIOTECH (75) – Arch Venture Partners $3B Startup Fund
BIOTECH (76) – Inception Therapeutics: Versant Ventures Discovery Engine
BIOTECH (77) – Repare Therapeutics: Camonsertib (ATR inhibitor)
BIOTECH (78) – Remiges Ventures US-Japan Cross-Over Biotech VC
BIOTECH (79) – Khosla Ventures’ Alex Morgan Interview
BIOTECH (80) – Areteia Therapeutics for repurposing ALS drug “Dexpramipexole” to Eosinophilic Asthma
BIOTECH (81) – Restore Vision’s Chimeric Rhodopsin Gene Therapy RV-001
BIOTECH (82) – Westlake Village BioPartners VC
BIOTECH (83) – Kelonia Therapeutics In vivo CAR-T through lentiviral vector
BIOTECH (84) – Sana Biotechnology Hypoimmune Islet Cells Control Blood Sugar in NHP without Immunosuppressant or insulin – Type 1 Diabetes
BIOTECH (85) – Firefly Bio: Degrader-Antibody Conjugate (DAC) Platform Company Series A $94M
BIOTECH (86) – Kyverna Therapeutics: Autoimmune Disease CAR-T Therapy with Ingenui-T Manufacturing
BIOTECH (87) – Gilead’s Magrolimab (Hu5F9-G4) CD47-SIRPα blocker with Azacitidine for AML Phase 3 ENHANCE Study Terminated & Solid Tumor Partial Clinical Hold
BIOTECH (88) – Recode Therapeutics: SORT LNP Delivery Platform Beyond Liver
BIOTECH (89) Cymabay Therapeutics: Seladelpar, an oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist
BIOTECH (90) – Iovance Biotherapeutics: FDA Accelerated Approval of lifileucel (Amtagvi), the first Tumour-Infiltrating Lymphocyte (TIL) Cancer Therapy
BIOTECH (91) – Replicate Bioscience: Self-Replicating mRNA against Therapy-Acquired Neoantigen
BIOTECH (92) – Vertex Non-Opioid Replacement NaV1.8 Inhibitor Suzetrigine (VX-548) Ph 3
BIOTECH (93) – RAPT Therapeutics: Zelnecirnon (RPT193, CCR4 Inhibitor) got Clinical Hold
BIOTECH (94) – Inventiva Pharma: Lanifibranor, a pan-PPAR agonist MASH 치료제 NATIV Phase 3
BIOTECH (95) – Ikena Oncology – Rebranding and Restructuring from Discovery to Clinical Focus
BIOTECH (96) – Janux Therapeutics: Tumor Activated Masked T-Cell Engager (TRACTr) Platform
BIOTECH (97) Tome Biosciences: Programmable Genomic Integration (PGI) Platform
BIOTECH (98) Basking Biosciences: Bruce Sullenger’s Reversable RNA Aptamer Platform
BIOTECH (99) BlueRock Therapeutics: Bemdaneprocel (BRT-DA01, MSK-DA01) – Autologous Stem Cell Therapy for Parkinson’s Disease
BIOTECH (100) PureHealth Tech: Glyph – Lymphatic Delivery Platform
BIOTECH (101) Krystal Biotech: Redosable HSV-1 vector gene therapy – Vijuvek (beremagene geperpavec)
BIOTECH (102) Elicio Therapeutics: Albumin-Hitchhiking Vaccine Amphiphile (AMP) Platform
BIOTECH (103) Prime Medicine: Prime Editing
BIOTECH (104) Novartis: Pluvicto (177Lu-PSMA-617) – the First Precision Radiopharmaceuticals
BIOTECH (105) Entos Pharmaceuticals: Fusogenix Proteolipid Vehicle (PLV) Platform
BIOTECH (106) Point Biopharma: Precision Radioligand Therapy (RLT)
BIOTECH (107) Sana Biotechnology의 Fusogen Platform 보류에 대한 소고
BIOTECH (108) Stapled Peptides: From Aileron to Fog Pharma
BIOTECH (109) MAIA Biotechnology: THIO – Telomere-Targeting Agent
BIOTECH (110) Gritstone Bio: self-amplifying RNA in chimpanzee adenovirus vector
BIOTECH (111) Flexus Biosciences: Treg Small Molecule Inhibitors
BIOTECH (112) Arcus Biosciences: Adenosine Immuno-Oncology Platform Company from Flexus Biosciences’ Spin-off by Terry Rosen and Juan Jaen
BIOTECH (113) GenEdit: Hydrophilic Polymer Nanoparticle Platform for Gene Delivery
BIOTECH (114) UCB Ra Pharmaceuticals: mRNA Display Platform for Macrocyclic Peptides
BIOTECH (115) Arvinas: PROTAC Platform Company
BIOTECH (116) Merus NV: Multispecific T Cell Engagers
BIOTECH (117) Amylyx Pharmaceuticals: ALS Drug Combo of Sodium Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA)
BIOTECH (118) John Crowley’s Love for Pompe Disease Drug Development from Novazyme Pharmaceuticals to Amicus Therapeutics
BIOTECH (119) Novo Nordisk: Semaglutide – Wegovy, Ozempic & Rybelsus for Type 2 Diabetes & Weight Loss
BIOTECH (120) Peptidream: Flexizyme-FIT-RaPID Platform for Macrocyclic Peptides
BIOTECH (121) Chugai Pharmaceutical – mRNA Display Platform & LUNA18 (pan-KRAS Inhibitor)
BIOTECH (122) Chugai Pharmaceutical – Eli Lilly: Orforglipron – Oral GLP-1R Agonist
BIOTECH (123) Curocell: Anbalcabtagene autoleucel is a novel anti-CD-19 CAR-T therapy – 큐로셀 안발셀
BIOTECH (124) HitGen: DNA-Encoded Library
BIOTECH (125) Bicycle Therapeutics: Bispecific Bicyclic Peptides Platform
BIOTECH (126) Accent Therapeutics: Small Molecules Targeting RNA-Modifying Protein
BIOTECH (127) Kenai Therapeutics: Allogeneic iPSC-Induced Neurology Cell Therapy
BIOTECH (128) Calithera Biosciences의 실패에 대한 소고
BIOTECH (129) VLP Therapeutics: Self-Amplifying mRNA in Virus-Like Particle
BIOTECH (130) Atlas Ventures: Option-to-Buy M&A Model – Nimbus Discovery & IFM Therapeutics
BIOTECH (131) Pearl Bio: Genomically Recorded Organisms with Synthetic Codons
BIOTECH (132) GRO Biosciences: Genomically Recorded Organisms
BIOTECH (133) Geron’s The First Telomerase Oligonucleotide Inhibitor, Imeltestat, Near FDA Approval
BIOTECH (134) Madrigal Pharmaceuticals: The First MASH Drug Rezdiffra (Resmetirom) Got FDA Approval.
BIOTECH (135) Ionis Pharmaceuticals: ION224 (Ionis-DGAT2rx) for MASH Phase 2 Result
BIOTECH (136) Latigo Biotherapeutics: Non-Opioid Pain Medicine – Nav1.8 Antagonist LTG-001
BIOTECH (137) Nogra Pharma: Mongersen – Oral SMAD7 Antisense Oligonucleotide
BIOTECH (138) Totus Medicines: DNA-Encoded Covalent Library & AI/ML
BIOTECH (139) Nxera Pharma (former Sosei Heptares): mini-G proteins (GPCR) & StaR (Stabilized Receptor) Platform
BIOTECH (140) Tr1X: T Regulatory Type 1 (Tr1) Cell Therapy for Autoimmune Disease
BIOTECH (141) Moonwalk Biosciences: Epigenome Editing with AI/ML for Methylome
BIOTECH (142) Shinobi Therapeutics: Allogeneic CD8αβ iPS-T Cell Platform
BIOTECH (143) EvolveImmune Therapeutics: Multifunctional T-Cell Engager Platform
BIOTECH (144) Carmot Therapeutics: Chemotype Evolution (CE) Platform to Lead to Lumakras (Sotorasib, AMG510) KRAS G12C Inhibitor
BIOTECH (145) Crinetics Pharmaceuticals: Specialty Endocrine Disorders
BIOTECH (146) Engrail Therapeutics: Neuroscience Asset Acquisition Platform
BIOTECH (147) Capstan Therapeutics: In Vivo CAR-T of targeted LNP-mRNA Platform
BIOTECH (148) Clasp Therapeutics: MANAFEST (Mutation Associated Neoantigen Functional Expansion of Specific T cells) & Modular T Cell Engager Platform
BIOTECH (149) Mirador Therapeutics: Prometheus Biosciences Reunion after Merck’s $11B M&A
BIOTECH (150) BioNTech SE의 Oncology Pipeline Review
BIOTECH (151) Nkarta Therapeutics – CAR-NK의 미래 (2부)
BIOTECH (152) Frontier Medicines: Covalent Molecular Glue Degraders by Chemoproteomics & AI/ML
BIOTECH (153) Fusion Pharmaceuticals: Targeted Alpha Particle Radiotherapeutics
BIOTECH (154) Cardior Pharmaceuticals: micro RNA Oligonucleotides Targeting Cardiology
BIOTECH (155) Stoke Therapeutics: Splicing Up-regulation by Antisense Oligonucleotides
BIOTECH (156) Merck – Should You Start a Chemistry Podcast?
BIOTECH (157) Dr. Josep Bassaganya-Riera’s LANCL-Targeting Autoimmune Drug Discovery – from Landos Biopharma to NImmune Biopharma
BIOTECH (158) Praxis Precision Medicines: CNS Small Molecules & Antisense Oligonucleotides Platform
BIOTECH (159) Avenzo Therapeutics: Turning Point Therapeutics Reunion – Acquisition of Early-Stage Oncology Small Molecules, ADCs from Chinese Biotech & US Biopharma
BIOTECH (160) Xilio Therapeutics: Tumor-Activated Immuno-Oncology
BIOTECH (161) Cerevel Therapeutics: Pfizer spin-off for Neuroscience Assets funded by Bain Capital
BIOTECH (162) Idorsia Pharmaceuticals: Johnson & Johnson/Actelion Merger Spinoff – first Endothelin Receptor Antagonist Aprocitentan FDA Approval
BIOTECH (163) Viking Therapeutics: VK2735 – Dual GLP-1/GIP Agonist
BIOTECH (164) Omega Therapeutics: Insulated Genomic Domain (IGD) Platform – Controllable Epigenomic Programming Platform
BIOTECH (165) Themis Bioscience GmbH: Merck’s wholly-owned subsidiary – Recombinant Measles Vector Vaccine Platform
BIOTECH (166) Mirati/BMS – Krazati (Adagrasib, KRAS G12C Inhibitor)
BIOTECH (167) Gritstone Bio: samRNA & chimpanzee adenovirus vector
BIOTECH (168) Obsidian Therapeutics: OBX-115 (on-switch cytoTIL Therapy)
BIOTECH (169) Insilico Medicine: INS018_055 – the first generative-AI drug at phase 2 clinical trials
BIOTECH (170) D&D Pharmatech: GLP-1R NLY01 Clinical Failure and Collaboration Deal with Metsera Pharma
BIOTECH (171) McKinsey Korea’s Next S-Curve Report 2023 – Biotech
BIOTECH (172) Cellares – Cell Shuttle Platform for CAR-T Automated Manufacturing
BIOTECH (173) Prolific Machines: Optogenetics-Based Meat Biomanufacturing
BIOTECH (174) Oral GI capsule device (1) Oral Antisense Oligonucleotide Delivery
BIOTECH (175) Vor Bio: Gene edited CD33 allogenic cell therapy
BIOTECH (176) 2022년에 최고의 주가상승률을 보였던 Top5 Biotech의 2025년 성적표
BIOTECH (177) Ethris GmbH – Inhalation mRNA asthma drug development
BIOTECH (178) Rocket Pharmaceuticals – How a venture capitalist created a gene therapy biotech
BIOTECH (179) Formation Bio – AI-Focused Clinical Trials Model of BD
BIOTECH (180) The Evolution of Biotech VC Funds
BIOTECH (181) Aitia: CRO-turned-Biotech – Digital Twin Platform
BIOTECH (182) Capstan Therapeutics #2 – Abbvie acquired with $2.1 Billion
BIOTECH (183) FDA Modernization Act 2.0 & 3.0에 대하여
BIOTECH (184) Ken Horne – 일본과 미국을 연결하는 크로스오버 벤처캐피탈리스트
BIOTECH (185) EsoBiotec – In Vivo CAR-T acquired by AstraZeneca
BIOTECH (187) Orbital Therapeutics: an in-vivo CAR-T company what BMS acquired at $1.5 Billion
BIOTECH (188) Tune Therapeutics: Epigenome Editing
BIOTECH (189) Sionna Therapeutics: Genzyme Spinoff for CFTR
BIOTECH (190) Metsera: Oral Peptide Drugs Acquired by Pfizer
BIOTECH (191) Adimab LLC: One-stop antibody shop with discovery and non-exclusive partnership
BIOTECH (192) Alloy Therapeutics: Better medicine together – drug discovery one-stop shop
BIOTECH (193) Bruth Booth – Atlas Ventures ‘ 20-year reflection (1) Science
BIOTECH (194) Carisma: CAR-M Therapy
BIOTECH (195) Bruce Booth – Atlas Ventures’ 20-year reflection (2) People
BIOTECH (196) Dren Bio: Myeloid Cell Engager (MCE)
BIOTECH (197) Bruce Booth – Atlas Ventures’ 20-year reflection (3) Business
BIOTECH (198) 바이오 전문가로서 책읽기 목록
My Biotech Memoir – Moderna (1) – Epilogue
My Biotech Memoir – Moderna (2) – 죽을때까지 이 걸음으로
My Biotech Memoir – Moderna (3) – 여호와이레 준비하시는 하나님
My Biotech Memoir – Moderna (4) – 나의 Mentor 이태석 박사님
My Biotech Memoir – Moderna (5) – 하나님이 나의 고용주이시다
My Biotech Memoir – Moderna (6) 주님과의 인격적인 만남과 선교에 대한 부르심
My Biotech Memoir – Moderna (7) – 독일에서 만난 선교사
My Biotech Memoir – Moderna (8) – 너는 요셉이다.
My Biotech Memoir – Moderna (9) – 변화의 시절
My Biotech Memoir – Moderna (10) – Merck’s wholly-owned subsidiary IDENIX Story
My Biotech Memoir – Moderna (11) – 욥기를 묵상하며 새롭게 된 Layoff 기간
My Biotech Memoir – Moderna (12) – siRNA Therapeutics의 임상개발과정과 중요한 발견들
My Biotech Memoir – Moderna (13) – 2015년 1월에 입사하다.
My Biotech Memoir – Moderna (14) – Year 2016
My Biotech Memoir – Moderna (15) 가장 힘들었던 2017년, 어머니의 말기암 선고, 암투병과 어머니의 장례식
My Biotech Memoir – Moderna (16) – 2018년 NASDAQ 상장사가 되다.
BOSTON DR LIM 